Brokerages Expect Novartis AG (NVS) Will Announce Earnings of $1.26 Per Share

Equities analysts expect Novartis AG (NYSE:NVS) to announce $1.26 earnings per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Novartis’ earnings, with the lowest EPS estimate coming in at $1.21 and the highest estimate coming in at $1.30. Novartis posted earnings per share of $1.28 in the same quarter last year, which would suggest a negative year over year growth rate of 1.6%. The business is scheduled to announce its next earnings results on Thursday, April 18th.

On average, analysts expect that Novartis will report full-year earnings of $5.35 per share for the current financial year, with EPS estimates ranging from $5.22 to $5.45. For the next year, analysts anticipate that the company will report earnings of $5.87 per share, with EPS estimates ranging from $5.73 to $6.05. Zacks’ EPS calculations are a mean average based on a survey of research analysts that that provide coverage for Novartis.

Novartis (NYSE:NVS) last issued its quarterly earnings results on Wednesday, January 30th. The company reported $1.24 EPS for the quarter, missing analysts’ consensus estimates of $1.33 by ($0.09). Novartis had a return on equity of 15.66% and a net margin of 24.30%. The company had revenue of $13.27 billion during the quarter, compared to the consensus estimate of $13.33 billion. During the same period in the prior year, the firm earned $1.21 earnings per share. The business’s revenue for the quarter was up 2.7% compared to the same quarter last year.

A number of brokerages have recently commented on NVS. Cowen raised Novartis from a “market perform” rating to an “outperform” rating and set a $88.03 price target on the stock in a research report on Sunday, December 2nd. JPMorgan Chase & Co. reissued a “neutral” rating on shares of Novartis in a research report on Wednesday, November 28th. Jefferies Financial Group reissued a “buy” rating and issued a $105.00 price target on shares of Novartis in a research report on Tuesday, December 11th. Goldman Sachs Group raised Novartis from a “neutral” rating to a “conviction-buy” rating in a research report on Friday, November 16th. Finally, Barclays cut Novartis from an “equal weight” rating to a “sell” rating in a research report on Friday, December 7th. Three equities research analysts have rated the stock with a sell rating, six have assigned a hold rating, seven have issued a buy rating and one has given a strong buy rating to the stock. Novartis has a consensus rating of “Hold” and an average price target of $90.94.

Shares of NVS traded up $0.39 during mid-day trading on Thursday, reaching $92.02. The company had a trading volume of 1,616,472 shares, compared to its average volume of 1,935,736. The company has a quick ratio of 0.97, a current ratio of 1.20 and a debt-to-equity ratio of 0.29. Novartis has a 52 week low of $72.30 and a 52 week high of $92.41. The stock has a market cap of $211.67 billion, a P/E ratio of 18.08, a P/E/G ratio of 1.96 and a beta of 0.67.

The firm also recently disclosed an annual dividend, which was paid on Wednesday, March 13th. Investors of record on Tuesday, March 5th were given a $2.8646 dividend. The ex-dividend date was Monday, March 4th. This is a boost from Novartis’s previous annual dividend of $2.33. This represents a yield of 3.27%. Novartis’s dividend payout ratio is 36.15%.

Hedge funds have recently added to or reduced their stakes in the stock. AlphaMark Advisors LLC bought a new position in Novartis in the 4th quarter valued at approximately $30,000. Laurel Wealth Advisors LLC purchased a new stake in Novartis during the 4th quarter valued at $35,000. Executive Wealth Management LLC purchased a new stake in Novartis during the 4th quarter valued at $36,000. Sonora Investment Management LLC raised its stake in Novartis by 93.9% during the 4th quarter. Sonora Investment Management LLC now owns 479 shares of the company’s stock valued at $41,000 after buying an additional 232 shares during the last quarter. Finally, Front Row Advisors LLC raised its stake in Novartis by 90.7% during the 4th quarter. Front Row Advisors LLC now owns 492 shares of the company’s stock valued at $42,000 after buying an additional 234 shares during the last quarter. 11.68% of the stock is currently owned by institutional investors and hedge funds.

Novartis Company Profile

Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company's Innovative Medicines segment offers patented prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, cardio-metabolic, and established medicine products.

Recommended Story: Cost of Equity For A Business, Investors

Get a free copy of the Zacks research report on Novartis (NVS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Novartis (NYSE:NVS)

Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.